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Translational Relevance 
Although the prognosis of patients with primary glioblastoma is generally poor, a 
minority of patients achieve longterm survival beyond 36 months. We here report that 
the rate of IDH1/2 mutations in such patients is 34% as opposed to 4.3% in controls 
and thus substantially increased. Molecular marker profiles of IDH1/2-mutant primary 
glioblastoma correspond to that of secondary glioblastomas which are typically 
IDH1/2-mutant, too. IDH1/2-wildtype glioblastoma patients with longterm survival 
exhibit no characteristic marker profile distinguishing them from ordinary IDH1/2-
wildtype glioblastoma patients with poor outcome, suggesting that host-derived 
factors, e.g., immune responsiveness, contribute to longterm survival in such 
patients. 
 
 
 
 
-4- 
 
Abstract 
Purpose: 
The determinants of longterm survival in glioblastoma have remained largely 
obscure. Isocitrate dehydrogenase (IDH) 1 or 2 mutations are common in WHO 
grade II and III gliomas, but rare in primary glioblastomas, and associated with longer 
survival.  
Experimental Design: 
We compared clinical and molecular characteristics of 69 patients with centrally 
confirmed glioblastoma and survival > 36 months (LTS-36), including 33 patients 
surviving > 60 months (LTS-60), with 257 patients surviving < 36 months. MGMT 
promoter methylation, 1p/19q codeletions, EGFR amplification, TP53 mutations and 
IDH1/2 mutations were determined by standard techniques. 
Results: 
The rate of IDH1/2 mutations in LTS-36 patients was 34% (23/67 patients) as 
opposed to 4.3% in controls (11/257 patients). Longterm survivors with IDH1/2 -
mutant glioblastomas were younger, had almost no EGFR amplifications, but 
exhibited more often 1p/19q codeletions and TP53 mutations than LTS patients with 
IDH1/2 wildtype glioblastomas. Longterm survivors with IDH1/2–wildtype showed no 
distinguishing features from other patients with IDH1/2-wildtype glioblastomas except 
a higher rate of MGMT promoter methylation. Similarly, among 11 patients with 
IDH1/2-mutant glioblastomas without longterm survival, the only difference to IDH1/2-
mutant longterm survivors was less frequent MGMT promoter methylation. Compared 
-5- 
 
with LTS-36 patients, LTS-60 patients had less frequently TP53 mutations and 
radiotherapy alone as initial treatment. 
Conclusions: 
IDH1/2 mutations define a subgroup of tumors of LTS patients that exhibit molecular 
characteristics of WHO grade II/III gliomas and secondary glioblastomas. 
Determinants of LTS with IDH1/2-wildtype glioblastomas, which exhibit typical 
molecular features of primary glioblastomas, beyond MGMT promoter methylation, 
remain to be identified. 
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Introduction 
According to the World Health Organization (WHO) classification of brain tumors, 
glioblastomas (WHO grade IV) are defined as malignant astrocytic tumors with 
necrosis or microvascular proliferation or both (1). They most commonly occur either 
de novo and are then referred to as primary glioblastomas. Less frequently, they 
develop by progression from lower grade gliomas and are then referred to as 
secondary glioblastomas. The overall prognosis of glioblastoma has remained poor. 
In a prospective study of 301 primary glioblastoma patients enrolled in the German 
Glioma Network (GGN), we observed a median overall survival (OS) of 12.5 months 
(2). However, a small fraction of patients survive for more than 36 months. We have 
previously arbitrarily defined these patients as longterm survivors (LTS) and clinically 
characterized these patients as being younger at diagnosis and having a good initial 
performance score. Molecularly, their tumors showed an increased rate of MGMT 
promoter hypermethylation (74%, versus 30-35% in the general glioblastoma 
population) (3). 
More recently, mutations in the gene encoding cytosolic NADP+-dependent 
isocitrate dehydrogenase 1 (IDH1) were identified in a minority of glioblastoma 
patients. They are more common in younger patients with primary glioblastoma and 
in patients with secondary glioblastoma and associated with increased OS (4, 5). In 
contrast, IDH1 mutations are detected in 60 to 90% of diffusely infiltrating gliomas of 
WHO grades II and III (6-12). IDH1 mutations occur exclusively in codon 132 and 
around 93% are R132H alterations (7). Moreover, mutations in the gene encoding 
the mitochondrial NADP+-dependent IDH2 were identified in around 3% of WHO 
grade II or III gliomas and secondary glioblastomas (7, 12). Thus, the differential 
distribution of IDH1/2 mutations among gliomas provided strong support for the 
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differentiation of secondary from primary glioblastoma and helped to molecularly 
dissect primary glioblastoma into distinct molecular subgroups (2, 10). These 
considerations led us to reanalyze and expand our original cohort of LTS 
glioblastoma patients (3) to address the question to what extent IDH1/2 mutations 
account for the LTS phenotype and to identify characteristic features of the IDH1/2-
wildtype LTS phenotype. 
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Material and Methods 
Patient recruitment and histology 
Sixty-nine patients with primary glioblastoma and an OS of longer > 36 months 
were identified by the 8 clinical centers and 2 associated clinical centers of the 
German Glioma Network (GGN; www.gliomnetzwerk.de). To be eligible for this 
analysis, it was required that the first histological diagnosis was that of a glioblastoma 
according to the WHO classification of central nervous system tumors (1) confirmed 
by central pathology review at the Brain Tumour Reference Center of the German 
Society of Neuropathology and Neuroanatomy (DGNN). Clinical and part of the 
molecular data of 36 patients have been published previously, but were updated and 
complemented for IDH1/2 mutation status for this report (3), data of 9 other patients 
have been included in another publication of the GGN (2). The study was approved 
by the local ethics committees at the GGN clinical centres and written informed 
consent was obtained from each patient. As a reference group, we used a cohort of 
257 primary glioblastoma patients published previously, but excluded all patients who 
survived for more than 36 months (2). 
 
DNA extraction and analysis for MGMT promoter methylation, 1p/19q co-deletion, 
EGFR amplification, and TP53 mutation 
DNA was extracted by standard methods either from formalin-fixed paraffin-
embedded tumor tissue or from unfixed frozen tumor tissue samples. MGMT 
promoter methylation analysis was carried out by methylation-specific PCR. EGFR 
gene dosage was determined by real-time PCR analysis. Losses on 1p and 19q were 
determined either by multiplex ligation-dependent probe amplification (MLPA) or by 
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loss of heterozygosity (LOH) analysis of five different microsatellite markers on each 
chromosomal arm. TP53 mutations were determined by single strand conformation 
polymorphism (SSCP) analysis followed by direct sequencing. Details of the 
respective molecular methods have been reported elsewhere (2, 3, 13). 
 
IDH1 and IDH2 mutation analysis 
IDH1 codon 132 and IDH2 codon 172 were analyzed by direct sequencing. In 
case of ambiguous results, the IDH1 or IDH2 sequences were amplified by a different 
set of primers (6, 7). In addition, 26 LTS patients that carried neither IDH1 nor IDH2 
mutations in the respective codons were tested for IDH1 codon 100 mutations (14). 
 
Statistical analysis 
Fisher’s exact test or the x2 tests were used to compare the frequencies of 
molecular aberrations and clinical data in the longterm survivor group versus the 
control group. Overall survival (OS) was calculated from the date of first surgery for 
glioblastoma until the time of death or last follow-up examination. Survival curves 
were compared using the log-rank test. Progression-free survival (PFS) was 
determined from day of first surgery until tumor progression, death, or end of follow-
up. Cox regression and multivariate logistic regression analyses were performed. 
Hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals (95% CI) 
were determined. All analyses were performed using IBM SPSS Statistics Version 
20.  
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Results 
Patient characteristics 
We identified 69 patients with a survival > 36 months with a median follow-up of 73 
months (LTS-36 cohort). Of these patients, 33 patients were ascertained to have 
survived for 60 months (LTS-60). These two cohorts were compared to a cohort of 
257 glioblastoma patients who survived for less than 36 months and had a median 
follow-up of 23.6 months. Demographic, clinical and molecular characteristics of 
these three cohorts are summarized in Table 1. Seventeen of 69 LTS-36 and 15 of 
33 LTS-60 patients are alive. LTS-36 patients were younger than control patients 
(p<0.001), but there was no enrichment of young patients in the LTS-60 group 
relative to the entire LTS-36 group of patients. The relative frequency of 
glioblastomas with oligodendroglial component was increased in the LTS cohorts. 
Initial KPS was similar among groups. There were fewer temporal tumors in LTS-36 
patients (p=0.185), but this difference was not significant, even if the analysis was 
restricted to the control cohort versus the LTS-60 cohort. LTS-36 patients had only 
slightly more often a gross total resection and slightly less often a biopsy than control 
patients (p=0.379). Compared with control patients, LTS-36 patients had more often 
two or more further surgical interventions (p<0.001), were more often reirradiated 
(p=0.066), and received one or two lines of salvage chemotherapy more often 
(p<0.001). First-line treatment after surgery was overall similar except that LTS-60 
patients received more often radiotherapy (RT) plus chemotherapy than RT alone 
relative to the other groups (n.s.). PFS with the first therapeutic intervention was five-
fold as long in LTS-36 patients compared with control patients. Seven patients in the 
LTS-60 cohort have not suffered progression: five are alive, one died of renal cell 
carcinoma and cause of death is unknown in the other patient. 
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Molecular markers 
The results of molecular analyses are summarized in Table 1 and Figure 1. LTS-36 
patients had more often MGMT promoter-methylated tumors than the control group 
(p<0.001). 1p/19q codeletions were rare and not more common in LTS patients. 
EGFR amplification was less common in LTS-36 patients (p=0.037). The relative 
frequencies of TP53 mutations were similar in LTS-36 and control patients (p=0.203). 
IDH1 mutations were much more common in the LTS-36 cohort (32.8%; 22/67) than 
in the control cohort (9/248) (p<0.001). Among LTS patients, an IDH1 R132H 
mutation was identified in 20 patients, an IDH1 R132S mutation in one patient and an 
R132C mutation in one patient. In the control group, 9 IDH1 mutations were found, all 
of the R132H type. One IDH2 mutation was identified in 65 LTS-36 patients and two 
IDH2 mutations in the control cohort. Among the 33 LTS-60 patients, fewer patients 
had TP53 mutations than in the entire LTS-36 cohort. We observed 13 patients in the 
LTS-60 cohort that had no salvage therapy, 6 with IDH1/2-mutant tumors and 7 with 
IDH1/2-wildtype tumors. The tumors of 6 patients with IDH1/2 mutation (median age 
39 years) were MGMT promoter-methylated and had no EGFR mutation. Six of 7 
patients with IDH1/2 wildtype tumors (median age 60 years) had MGMT promoter 
methylation and 4 of 6 patients had tumors without EGFR mutation.  
 
Prognostic factors for LTS-36 
Next we asked which factors influenced the likelihood to become a LTS-36 patient 
and performed a multivariate logistic regression analysis. We included age (<50 vs. 
>50), KPS (≥ 80 vs. <80), extent of resection (total vs. no total) and four genetic 
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alterations (MGMT promoter methylation, IDH1/2 mutation, EGFR amplification, 
TP53 mutation) as main factors. The most important prognostic factors for surviving 
for at least 36 months were MGMT status, IDH1/2 status and age (Table 2). Table 3 
shows a comparison of control patients as well as LTS-36 and LTS-60 patients with 
versus without IDH1/2-mutant tumors. 
 
IDH-mutant versus IDH-wildtype glioblastoma with LTS 
LTS patients with IDH1/2-mutant tumors were younger (p=0.001), had more often 
frontal as opposed to temporal or parietal tumors (p=0.013), had more often an 
oligodendroglial component (p=0.099), and were treated with RT alone initially more 
often (p=0.169). The molecular profile of IDH1/2-mutant tumors of LTS-36 patients 
was characterized by a higher rate of MGMT promoter methylation (p=0.307), 1p/19q 
codeletions (p=0.046), and TP53 mutations (p=0.345), and the absence of EGFR 
amplification (p=0.001). Individual profiles are provided in Supplementary Tables 1 
and 2. Among patients with wildtype IDH1/2 status, MGMT promoter methylation 
provided a HR for death of 0.47 (95% CI 0.22-1.0, p=0.053). Only two patients had 
IDH1/2-mutant tumors lacking MGMT promoter methylation. Conversely, wildtype 
TP53 status conferred a risk reduction both in patients with IDH1/2-mutant (0.28, 
95% CI 0.09-0.82, p=0.020) and IDH1/2 wildtype (0.59, 95% CI 0.24-0.1.45, 
p=0.250) tumors. We also assessed survival probability by molecular marker status 
in glioblastoma patients surviving for at least 36 months (LTS-36 cohort). Figure 2 
shows that, among the LTS-36 patients, IDH1/2 status was prognostically irrelevant 
(p=0.414) whereas MGMT promoter methylation (p=0.078), wildtype TP53 status 
(p=0.015) and absence of EGFR amplification (p=0.106), with descending magnitude 
of effect, were associated with increased survival. Figure 3 shows the relative 
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distribution of patients with combinations of IDH1/2 mutation and MGMT promoter 
methylation among the three cohorts, control, LTS-36 and LTS-60 patients.  
 
IDH1/2-mutant LTS versus IDH1/2-mutant non-LTS 
Columns 2 and 4 of table 3 allow to compare 23 LTS-36 patients with IDH1/2 
mutations versus 11 patients with IDH1/2 mutations who survived for less than 36 
months. Their median survival was 12 months and thus similar to the median survival 
of the general non-LTS cohort (Table 1). Death from tumor progression was 
confirmed in all 11 patients. None of these tumors had an oligodendroglioma 
component. The only other remarkable difference between these two cohorts of 
patients with IDH1/2-mutant glioblastoma were the rates of MGMT promoter 
methylation: there were 17 methylated, four weakly methylated and only two 
unmethylated tumors in IDH1/2-mutant LTS, but four methylated, one weakly 
methylated and six unmethylated tumors in the IDH1/2-mutant control patients 
(p=0.016). 
 
IDH1/2-wildtype LTS versus IDH1/2-wildtype non-LTS 
Columns 3 and 5 of table 3 allow to compare 44 LTS-36 patients without IDH1/2 
mutations versus 229 patients without IDH1/2 mutations who survived for less than 
36 months. The major differences between these groups were (expectedly) a higher 
number of patients who were not treated at all after surgery among control patients 
and a strong enrichment of patients with MGMT promoter-methylation in the LTS 
group. 
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Discussion 
The clinical and molecular determinants of extended survival in glioblastoma remain 
uncertain, but are currently being elucidated using various approaches. Using one of 
the largest patient populations ever reported, the present study defines MGMT 
status, IDH1/2 status and age as the most important prognostic factors for surviving 
the diagnosis of primary glioblastoma for at least 36 months (Table 2). Most LTS 
patients showed a classical glioblastoma morphology, although there was an 
enrichment for glioblastoma with oligodendroglial component in the LTS patients, in 
particular in the LTS-60 group. This histological subtype was more common in 
IDH1/2 mutant tumors (Table 3). In contrast, extent of resection was not different 
between control group and LTS-36 patients. Moreover, although fewer patients in the 
LTS-60 group received RT alone as initial treatment, no such difference was seen 
between LTS-36 and control patients, and the differences in salvage treatment are 
unlikely to account for LTS since one might well argue that patients with less 
aggressive tumors are more likely to be eligible for multiple salvage therapies. 
We delineate two main cohorts of primary glioblastoma patients with extended 
survival beyond 36 months, patients with IDH1/2 mutations and patients without 
IDH1/2 mutations. Furthermore, IDH1/2-wildtype tumors with and without MGMT 
promoter methylation can be distinguished (Figure 3). IDH1/2 mutations have been 
associated with overall better prognosis across all diffusely infiltrating malignant 
astrocytic entities (9, 10, 12, 15, 16) and their absence in elderly glioblastoma 
patients may explain in part why age is a negative prognostic factor in this disease 
(17). However, it has never been explored whether tumors with IDH1/2 mutations are 
enriched in longterm survivors of glioblastomas. Importantly, the present study only 
included patients with primary glioblastoma, that is, there was no evidence of a prior 
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lower-grade lesion in any of these patients. We report a rate of IDH1/2 mutations of 
34.3% (23/67) in LTS-36 patients which was much higher than in the general 
population of glioblastoma patients (5-10%). The molecular profile of these LTS-36 
patients with IDH1/2-mutant primary glioblastoma was characterized by an increased 
prevalence of TP53 mutations and the absence of EGFR amplification (Table 3). 
Although a less malignant precursor lesion escaped clinical detection in this group of 
patients, the pattern of molecular alterations in their tumors was typical of secondary 
glioblastoma (9). Accordingly, the concept of primary and secondary glioblastoma 
should probably be replaced by a molecular concept, e.g., of IDH1/2-mutant 
glioblastoma rather than by the absence or presence of a clinically recognized 
precursor lesion, because future therapeutic decision making is likely to be more 
commonly based on molecular profiles. 
The biological consequences of IDH1/2 mutations are currently being elucidated. 
Mutant IDH1 proteins generate excessive amounts of 2-hydroxyglutarate (2HG) from 
α-ketoglutarate (18). 2HG is a competitive inhibitor of various α-ketoglutarate-
dependent dioxygenases (19). Accordingly, increased 2HG levels are predicted to 
inhibit histone demethylases and TET hydroxylases, thereby preventing histone 
demethylation and increasing promoter methylation of multiple genes (19, 20), 
including MGMT promoter methylation, and explaining why IDH1/2-mutant gliomas 
commonly exhibit the glioma-CpG island methylator phenotype (G-CIMP) (21, 22). 
Both LTS cohorts, patients with and without IDH1/2 mutations, share an increased 
prevalence of MGMT promoter methylation. All patients received alkylating agent 
chemotherapy at least once in the course of disease. Accordingly, it is impossible to 
dissect a prognostic versus predictive impact of MGMT promoter methylation in this 
cohort. Since most IDH1/2-mutant tumors exhibit MGMT promoter methylation, an 
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independent association of MGMT promoter methylation with outcome cannot be 
assessed in this cohort. The frequent MGMT promoter methylation in IDH1/2 mutant 
glioblastomas suggests that MGMT belongs to the G-CIMP gene set (23). This 
association may explain why MGMT promoter methylation in patients with anaplastic 
gliomas, tumors with a high frequency of IDH1/2 mutations, confers a prognostic 
benefit independent of the therapy regime (24, 25). In contrast, MGMT promoter 
methylation retained an (almost significant) prognostic significance in patients with 
IDH1/2 wildtype glioblastoma. The molecular mechanisms inducing MGMT promoter 
methylation in glioblastomas of such patients remain to be identified. The speculation 
that these tumors carry alterations in other genes involved in the same pathway as 
IDH1/2 has not been substantiated so far and is unlikely, given their differential 
genomic and epigenomic profiles. We confirm a lower rate of EGFR amplification in 
the LTS-36 cohort (26), but this can now be linked to its virtual absence in patients 
with IDH1/2-mutant tumors. Interestingly, the EGFR amplification rate in IDH1/2-
wildtype tumors was similar in LTS-36 patients (43.2%) and in the control cohort 
(45.5%). Somewhat surprisingly, among the LTS-36 patients, patients with TP53 
mutant tumors had an inferior outcome. This observation corresponds to a similar 
observation at longterm follow-up in low grade astrocytoma patients (27) and was 
more prominent in the IDH1/2-mutant LTS-36 patients. Altogether, the determinants 
of longterm survival in patients with IDH1/2 wildtype glioblastomas, which exhibit the 
typical molecular phenotype of glioblastomas, beyond MGMT promoter methylation 
remain to be identified, and even the absence of both IDH1/2 mutations and MGMT 
promoter methylation does not preclude longterm survival. Finally, since the report of 
a small, nine patient series in 2006 (28), the present study represents the only 
characterization of primary glioblastoma patients surviving for 5 years or more, and 
molecular data on such patients have never been reported before. 
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Given limitations of tissue availability, we were unable to explore whether the LTS 
phenotype in our cohort is linked to recently characterized gene expression or DNA 
methylation signatures (29-31). The first high-throughput approaches have indeed 
suggested links between LTS and decreased retinoic acid signaling (32), enhanced 
immune-related gene expression (33), or distinct DNA methylation profiles (34), but 
more studies with larger patient populations seem to be required to decide whether 
tumor rather than host factors are chiefly responsible for LTS. 
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Table 1. Summary of patient characteristics. 
 
 Control group 
(OS < 36 
months) 
n=257 
LTS > 36 
months 
 
n=69 
LTS > 60 
months 
 
n=33 
Age at diagnosis    
  Median (years) 62 49 49 
  Range (years) (19-86) (21-74) (22-74) 
Gender    
  Male 158 (61.5%) 35 (50.7%) 19 (57.6%) 
  Female   99 (38.5%) 34 (49.3%) 14 (42.4%) 
Histological subtype    
  Glioblastoma 235 (91.4%) 60 (87.0%) 28 (84.8%) 
  Glioblastoma olig. comp. 5 (1.9%) 4 (5.8%) 4 (12.1%) 
  Gliosarcoma 7 (2.7%) 2 (2.9%) 1 (3.0%) 
  Giant cell glioblastoma 7 (2.7%) 3 (4.3%) - 
  Glioblastoma with single giant cells 3 (1.2%) - - 
Survival 
  Median follow-up (months) 
  Median PFS (months, 95% CI) 
 
  Median OS (months, 95% CI) 
 
  Alive at last follow-up 
 
23.6 
6.0 (5.4-6.6) 
 
10.6 (9.6-
11.7) 
4(1.6 %) 
 
73.0 
31.7 (25.8-
37.6) 
60.2 (52.8-
67.5) 
17 (24.6%) 
 
73.6 
45.9 (38.1-
53.7) 
83.0 (71.1-
94.5) 
15 (45.5%) 
KPS at diagnosis    
  90-100 106 (41.9%) 27 (41.5%) 13 (41.9%) 
  70-80 119 (47.0%) 32 (49.2%) 16 (51.6%) 
  <70   28 (11.1%) 6 (9.2%) 2 (6.5%) 
  No data 4 4 2 
Tumor location    
  Frontal   59 (23.1%) 17 (24.6%) 8 (24.2%) 
  Temporal   72 (28.2%) 14 (20.3%) 6  (18.2%) 
  Parietal   31 (12.2%) 11 (15.9%) 6  (18.2%) 
  Occipital 12 (4.7%) 1 (1.4%) - 
  Not localized to one site 60 (23.5%) 20 (29.0%) 9 (27.3%) 
  Multifocal 
  Others 
  3 (1.2%) 
18 (7.1%) 
1 (1.4%) 
5 (7.2%) 
1 (3.0%) 
3 (9.1%) 
  No data 2  - - 
Surgery    
  Gross total resection 104 (40.9%) 32 (49.2%) 16 (50.0%) 
  Subtotal resection (50-99%)   95 (37.4%) 21 (32.3%) 12 (37.5%) 
  Partial resection (<50%)   29 (11.4%)   8 (12.3%) 3 (9.4%) 
  Biopsy   26 (10.2%) 4 (6.2%) 1 (3.1%) 
  No data 3 4 1 
First-line therapy    
  RT alone   61 (24.1%) 19 (27.5%)  5 (15.2%) 
  RT plus TMZ 151 (58.8%) 37 (53.6%) 21 (63.6%) 
  RT plus nitrosourea 
  RT plus PC 
  TMZ alone 
  2 (0.8%) 
  1 (0.4%) 
10 (3.9%) 
11 (15.9%) 
- 
- 
  6 (18.2%) 
- 
- 
  Procarbacine plus lomustine alone 
  Nitrosourea alone 
  - 
  1 (0.4%) 
1 (1.4%) 
- 
- 
- 
  No therapy   30 (11.6%) 1 (1.4%) 1 (3.0%) 
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Salvage therapies    
  Surgery (1) 
  Surgery (2) 
  Surgery (>2) 
  53 (20.6%) 
11 (4.3%)  
   1 (0.4%) 
16 (23.2%) 
8 (11.6%) 
5 (7.2%) 
7 (21.2%) 
4 (12.1%) 
    3 (9.1%)  
  RT (first) 
  RT (reirradiation) 
4 (1.6%) 
19 (7.4%) 
1 (1.4%) 
10(14.5%) 
1 (3.0%) 
5 (15.2%) 
  Chemotherapy (1) 
  Chemotherapy (2) 
  Chemotherapy (3) 
  Chemotherapy (>3) 
53 (20.6%) 
25 (9.7%) 
6 (2.3%) 
1 (0.4%) 
20 (29.0%) 
11 (15.9%) 
5 (7.2%) 
4 (5.8%) 
13 (39.4%) 
4 (12.1%) 
- 
2 (6.1%) 
      
  Other medical therapies (1) 
  Other medical therapies (>1) 
Including every drug not classified as 
chemotherapy, e.g., bevacizumab and 
tyrosine kinase inhibitors 
20 (7.8%) 
4 (1.6%) 
7 (10.1%) 
1 (1.4%) 
2 (6.1%) 
- 
  None 145 (56.4%) 21 (30.4%) 8 (22.2%) 
    
MGMT promoter methylation status 
(MSP) 
   
  Methylated   85 (33.6%) 41 (60.3%) 22 (66.7%) 
  Weakly methylated 15 (5.9%) 16 (23.5%)  7 (21.2%) 
  Unmethylated 
  No data 
153 (60.5%) 
4 
11 (16.2%) 
1 
 4 (12.1%) 
- 
1p/19q codeletion    
  Yes 20 (8.4%) 6 (9.7%) 2 (6.5%) 
  No 217 (91.6%) 56 (90.3%) 29 (93.5%) 
  No data 20 7 2 
EGFR amplification    
  Yes 109 (43.4%) 20 (29.4%)   7 (21.2%) 
  No 142 (56.6%) 48 (70.6%) 26 (78.8%) 
No data 6 1 - 
TP53 mutation    
  Yes   37 (15.0%) 14 (21.5%)  4 (12.5%) 
  No 210 (85.0%) 51 (78.5%) 28 (87.5%) 
  No data 10 4 1 
IDH1 mutation    
  Yes 9 (3.6%) 22 (32.8%) 12 (36.4%) 
  No 239 (96.4%) 45 (67.2%) 21 (63.6%) 
  No data  9 2 - 
IDH2 mutation    
  Yes 2 (0.8%) 1 (1.5%) 1 (3.1%) 
  No 239 (99.2%) 64 (98.5%) 31 (96.9%) 
  No data 16 4 1 
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Table 2. Multivariate logistic regression model for LTS-36 vs. control group 
 
 OR 95%-CI P value 
Age 
< 50 vs. > 50 (ref.) 
5.0 2.3 to 10.5 < 0.001 
KPS 
≥ 80 vs. < 80 (ref.) 
1.5 0.6 to 3.6 0.359 
Extent of resection 
total vs. no total (ref.) 
1.1 0.5 to 2.2 0.806 
IDH1/2 
mutant vs. wildtype (ref.) 
4.0 1.5 to 11.0 0.007 
MGMT 
methylated vs. unmethylated (ref.) 
6.5 2.9 to 14.4 < 0.001 
EGFR 
not amplified vs. amplified (ref.) 
1.4 0.6 to 3.0    0.409 
TP53 
mutant vs. wildtype (ref.) 
1.0 0.4 to 2.6    0.954 
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Table 3. Comparison of control group, LTS-36 and LTS-60 patients: IDH1/2 mutant versus IDH1/2 wildtype 
 
 Control group  
(OS < 36 
months) 
IDH1/2 
mutant 
n=11 
 
Control group  
(OS < 36 
months) 
IDH1/2 
wildtype 
n=229 
 
LTS-36 
IDH mutant 
n=23 
LTS-36 
IDH wildtype 
n=44 
LTS-60 
IDH mutant 
n=13 
LTS-60 
IDH wildtype 
n=20 
Age at diagnosis       
  Median (years) 44 63 41 55 39 60 
  Range (years) 27-79 19-86 (22-71) (21-74) (22-54) (32-74) 
Gender       
  Male 5 (45.5%) 141 (61.6%) 12 (52.2%) 23 (52.3%) 7 (53.8%) 12 (60.0%) 
  Female 6 (54.5%) 88 (38.4%) 11 (47.8%) 21 (47.7%) 6 (46.2%)   8 (40.0%) 
Histological subtype       
  Glioblastoma 9 (81.8%) 209 (91.3%) 20 (87.0%) 38 (86.4%) 10 (76.9%) 18 (90.0%) 
  Glioblastoma olig. comp.      - 5 (2.2%)   3 (13.0%) 1 (2.3%)   3 (23.1%) 1 (5.0%) 
  Gliosarcoma      - 7 (3.1%) - 2 (4.5%) - 1 (5.0%) 
  Giant cell glioblastoma      - 7 (3.1%) - 3 (6.8%) - - 
  Glioblastoma with single giant cells 2 (18.2%) 1 (0.4%)     
Survival 
  Median follow-up (months) 
  MedianPFS (months, 95% CI) 
  Median OS (months, 95% CI) 
  Alive at last follow-up 
 
- 
6.8 (3.0-10.5) 
11.8 (5.1-8.5) 
0 
 
21.1 
6.0 (5.4-6.6) 
10.5 (9.5-11.6) 
3 (1.3%) 
 
73.9 
31.7 (13.9-49.5) 
64.8 (47.4-82.2) 
8 (34.8%) 
 
73.0 
30.8 (25.3-36.4) 
59.1 (51.0-67.2) 
9 (20.5%) 
 
73.9 
47.5 (0-97.2) 
103.1 (-) 
8 (61.5%) 
 
73.6 
44.8 (33.0-56.5) 
75.4 (69.3-81.4) 
7 (35.0%) 
KPS at diagnosis       
  90-100 6 (54.5%)   91 (40.4%)   7 (30.4%) 18 (46.3%)   5 (38.5%)   8 (44.4%) 
  70-80 3 (27.3%) 110 (48.9%) 14 (60.9%) 19 (43.9%)   7 (53.8%)   9 (50.0%) 
  <70 2 (18.2%)   24 (10.7%) 2 (8.7%) 4 (9.8%) 1 (7.7%) 1 (5.6%) 
  No data - 4 - 3 - 2 
Tumor location       
  Frontal   4 (36.4%)   52 (22.8%)   9 (39.1%)   8 (18.2%)   5 (38.5%)  3 (15.0%) 
  Temporal 1 (9.1%)   64 (28.1%) 1 (4.3%) 13 (29.5%) -  6 (30.0%) 
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  Parietal   3 (27.3%)   27 (11.8%) 1 (4.3%)   8 (18.2%) 1 (7.7%)  5 (25.0%) 
  Occipital 
  Not localized to one site 
   - 
  3 (27.3%) 
11 (4.8%) 
  55 (24.1%) 
1 (4.3%) 
  9 (39.1%) 
- 
11 (25.0%) 
- 
  5 (38.5%) 
- 
 4 (20.0%) 
  Multifocal    -   3 (1.3%) - 1 (2.3%) - 1 (5.0%) 
  Others    - 16 (7.0%) 2 (8.7%) 3 (6.8%)   2 (15.4%) 1 (5.0%) 
  No data - 1 - - - - 
Surgery       
  Gross total resection 6 (54.5%)   95 (42.0%) 10 (45.5%) 22 (53.7%) 7 (58.8%)  9 (47.4%) 
  Subtotal resection (50-99%) 2 (18.2%)   85 (37.6%)   7 (31.8%) 13 (31.7%) 4 (30.8%)  8 (42.1%) 
  Partial resection (<50%) 3 (27.3%) 22 (9.7%)   4 (18.2%) 4 (9.8%) 2 (15.4%) 1 (5.3%) 
  Biopsy    -   24 (10.6%) 1 (4.5%) 2 (4.9%) - 1 (5.3%) 
  No data - 3 1 3 - 1 
Review diagnosis       
  Glioblastoma 11 (100.0%) 215 (93.9%) 23 (100.0%) 39 (88.6%) 13 (100.0%) 19 (95.0%) 
  Gliosarcoma   - 7 (3.1%) - 2 (4.5%) - 1 (5.0%) 
  Giant cell glioblastoma   - 7 (3.1%) - 3 (6.8%) - - 
First-line therapy       
  RT alone 2 (18.2%) 58 (25.3%)   9 (39.1%) 10 (22.7%)   4 (30.8%) 1 (5.0%) 
  RT plus TMZ 8 (72.7%) 132 (57.6%) 10 (43.5%) 25 (56.8%)   7 (53.8%) 14 (70.0%) 
  RT plus nitrosourea - 2 (0.9%) 2 (8.7%)   9 (20.5%) 1 (7.7%)   5 (25.0%) 
  Procarbacine plus 
  lomustine alone 
 
- 
 
- 
1 (4.3%) - - 
 
- 
  RT plus PC - 1 (0.4%)     
  TMZ alone - 9 (3.9%)     
  Nitrosourea alone 1 (9.1%) -     
  No therapy - 27 (11.8%) 1 (4.3%) - 1 (7.7%) - 
Salvage therapies        
  Surgery (1) 2 (18.2%) 50 (21.8%)   4 (17.4%) 12 (27.3%) -   7 (35.0%) 
  Surgery (2) 
  Surgery (>2) 
  RT (first) 
1 (9.1%) 
- 
1 (9.1%) 
9 (3.9%) 
1 (0.4%) 
3 (1.3%) 
  5 (21.7%) 
- 
2 (8.7%) 
2 (4.5%) 
  5 (13.9%) 
- 
  3 (23.1%) 
- 
1 (7.7%) 
1 (5.0%) 
  3 (15.1%) 
- 
  RT (reirradiation) 
 
  Chemotherapy (1) 
  Chemotherapy (2) 
1 (9.1%) 
 
3 (27.3%) 
2 (18.2%) 
17 (7.4%) 
 
47 (20.5%) 
23(10.0%) 
3 (13.0%) 
 
  8 (34.8%) 
  3 (13.0%) 
  8 (18.2%) 
 
13 (29.5%) 
  8 (18.2%) 
1 (7.7%) 
 
  5 (38.5%) 
1 (7.7%) 
  4 (20.0%) 
 
  9 (45.0%) 
  3 (15.0%) 
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  Chemotherapy (3) 
  Chemotherapy (>3) 
 
  Other med. therapies (1) 
- 
- 
 
1 (9.1%) 
5 (2.2%) 
1 (0.4%) 
 
18 (7.9%) 
- 
1 (4.3%) 
 
1 (4.3%) 
  5 (11.4%) 
3 (6.8%) 
 
  6 (13.6%) 
- 
1 (7.7%) 
 
1 (7.7%) 
- 
1 (5.0%) 
 
1 (5.0%) 
  Other med. therapies (>1) - 3 (1.3%) - 1 (2.3%) - - 
  None 5 (45.5%) 127 (55.5%)   8 (34.8%) 13 (29.5%)   6 (46.2%)   7 (35.0%) 
MGMT promoter methylation status       
  Methylated   4 (36.4%)   76 (33.8%) 17 (73.9%) 24 (54.5%) 10 (76.9%) 12 (59.1%) 
  Weakly methylated 1 (9.1%) 13 (5.8%)  4 (17.4%) 11 (25.0%)   2 (15.4%)   5 (22.7%) 
  Unmethylated   6 (54.5%) 136 (60.4%) 2 (8.7%)  9 (20.5%) 1 (7.7%)   3 (18.2%) 
  1p/19q codeletion       
  Yes 2 (20.0%) 18 (8.4%)   4 (19.0%) 1 (2.6%)   2 (16.7%) - 
  No 8 (80.0%) 196 (91.6%) 17 (81.0%) 38 (97.4%) 10 (83.3%) 19 (100.0%) 
  No data 1 15 2 5 1 1 
  EGFR amplification       
  Yes 1 (9.1%) 102 (45.5%) 1 (4.3%) 19 (43.2%) -   7 (35.0%) 
  No 10 (90.9%) 122 (54.5%) 22 (95.7%) 25 (56.8%) 13 (100.0%) 13 (65.0%) 
  TP53 mutation       
  Yes 4 (40.0%)  32 (14.5%)   7 (30.4%)   7 (17.5%)   2 (15.4%)   2 (10.5%) 
  No 6 (60.0%) 189 (85.5%) 16 (69.6%) 33 (82.5%) 11 (84.6%) 17 (89.5%) 
  No data 1 8  4  1 
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Figure legend 
 
Figure 1. Relative frequency of molecular marker aberrations by cohort: IDH1/2 
mutation status, MGMT promoter methylation status, TP53 mutation status or EGFR 
amplification status in control (A), LTS-36 (B) and LTS-60 (C) patients. 
 
Figure 2. Survival by molecular marker status in the LTS-36 cohort. OS is shown for 
the LTS-36 patients (left) and compared with the control cohort (right) stratified by 
IDH1/2 mutation status (A,E), MGMT promoter methylation status (B,F), TP53 
mutation status (C,G) or EGFR amplification status (D,H). 
 
Figure 3. Distribution of glioblastomas by IDH1/2 mutation and MGMT promoter 
methylation status among the three patient groups: control (A), LTS-36 (B) and LTS-
60 (C) patients. 
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Supplementary Table 1. Individual profiles of LTS-36 patients with IDH1/2-mutant 
glioblastomas. 
 
No Age Gender MGMT promoter 
methylation 
1p/19q 
codeletion 
EGFR 
amplification 
TP53 
mutation 
1 36 male methylated no no no 
2 50 male methylated yes yes yes 
3 39 female methylated no no no 
4 35 female methylated no no no 
5 41 male methylated no no yes 
6 37 male methylated n.a. no no 
7 44 female methylated no no no 
8 24 male methylated no no no 
9 71 female methylated no no no 
10 48 female methylated yes no no 
11 54 male weakly methylated no no no 
12 50 female methylated no no no 
13 44 male unmethylated no no no 
14 45 female methylated no no no 
15 55 female methylated no no yes 
16 29 female weakly methylated no no yes 
17 39 female methylated yes no no 
18 22 male methylated no no yes 
19 24 female unmethylated no no yes 
20 45 male methylated yes no no 
21 55 male weakly methylated no no no 
22 38 male methylated n.a. no yes 
23 35 male weakly methylated no no no 
 
 
Supplementary Table 2. Individual profiles of LTS-36 patients with IDH1/2-wildtype 
glioblastomas. 
 
No Age Gender MGMT promoter 
methylation 
1p/19q 
codeletion 
EGFR 
amplification 
TP53 
mutation 
1 60 female methylated no no no 
2 57 male weakly methylated no no n.a. 
3 52 female methylated no yes no 
4 56 female methylated no yes no 
5 63 female methylated no yes no 
6 25 female methylated no no yes 
7 49 female weakly methylated n.a. no no 
8 71 male methylated no no no 
9 56 female weakly methylated no yes no 
10 66 male weakly methylated n.a. yes n.a. 
11 56 male methylated no yes no 
12 40 female weakly methylated no no no 
13 50 male weakly methylated no yes no 
14 32 female methylated no no yes 
15 51 male unmethylated no no no 
16 62 male weakly methylated no no no 
17 74 female unmethylated no yes no 
18 39 female methylated no no no 
19 36 female methylated no no no 
20 57 male methylated no no no 
21 41 male methylated no no no 
22 60 female methylated no yes no 
23 68 male methylated no yes no 
24 52 male methylated no yes yes 
25 55 female weakly methylated no no no 
26 48 male methylated no yes no 
27 56 female methylated no yes no 
28 49 female unmethylated yes no yes 
29 48 male methylated no yes no 
30 44 male unmethylated no no no 
31 59 male methylated no no no 
32 60 male weakly methylated no yes no 
33 65 male unmethylated no yes no 
34 43 male methylated no no no 
35 64 female weakly methylated no no yes 
36 42 male weakly methylated n.a. no yes 
37 42 female methylated no yes n.a. 
38 62 male methylated no yes no 
39 60 female methylated n.a. yes n.a. 
40 31 female unmethylated no no no 
41 60 male methylated no no no 
42 21 female unmethylated no no no 
43 29 male methylated no no no 
44 59 male unmethylated n.a. no yes 
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